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Infection of HeLa cells with poliovirus leads to rapid shut-off of host cell transcription by RNA polymerase II. Previous
results have suggested that both the basal transcription factor TBP (TATA-binding protein) and transcription activator
proteins such as CREB (cyclic AMP-responsive element-binding protein) and Oct-1 (the octamer-binding factor) are cleaved
by the viral-encoded protease, 3CPro. Here we demonstrate that the transcriptional activator (and tumor suppressor) p53 is
degraded by the viral protease 3C both in vivo and in vitro. Unlike other transcription factors that are directly cleaved by 3Cpro,
degradation of p53 requires a HeLa cell activity in addition to 3CPro. The degradation of p53 by 3CPro does not appear to
involve the ubiquitin pathway of protein degradation. Vaccinia virus infection of HeLa cells leads to inactivation of the cellular
activity required for 3CPro-mediated degradation of p53. The vaccinia-encoded protein (CrmA) is known to inhibit caspase I
(ICE protease) that converts inactive IL-1b to an active secreted form. Incubation of HeLa cells with caspase I inhibitor
Z-VAD-fmk does not interfere with 3CPro-mediated degradation of p53. The cellular activity present in extracts of HeLa cells
can be fractionated through phosphocellulose. A partially purified fraction that elutes at 0.6 M KCl from phosphocellulose
contains the activity that degrades p53 in a 3CPro-dependent manner. These results suggest that both poliovirus-encoded
Proprotease 3C and a cellular activity are required for the degradation of p53 observed in cells infected with poliovirus. © 2001
Elsevier ScienceINTRODUCTION
Infection of human cells with poliovirus (PV) leads to
rapid inhibition of host cell RNA synthesis catalyzed by
RNA polymerases I (Pol I), Pol II, and Pol III (Kaariainen
and Ranki, 1984). It has been shown that the inhibition of
cellular transcription observed in vivo can be recapitu-
lated in vitro by using extracts prepared from mock- or
poliovirus-infected cells (Crawford et al., 1981). For each
of the three polymerase systems, in vitro analysis has
revealed that the inhibition of transcription by poliovirus
infection is a consequence of inactivation of specific
transcription factors (Clark and Dasgupta, 1990; Clark et
al., 1991, 1993; Kliewer et al., 1988; Rubinstein et al.,
1992). We have shown that the TATA-binding protein
(TBP), the DNA-binding subunit of transcription factor
TFIID, is proteolytically cleaved by the virus-specific pro-
tease 3CPro (Clark et al., 1993; Yalamanchili et al., 1996;
1997a). This cleavage leads to loss of formation of the
TBP–TATA box complex, resulting in inhibition of TATA-
and initiator-mediated basal transcription (Yalamanchili
et al., 1996). Similarly, a Pol III DNA-binding transcription
factor, TFIIIC, is cleaved and inactivated by 3CPro (Clark et
al., 1991). The a subunit of TFIIIC which contacts the Pol
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260III promoter is the target of the viral protease 3CPro (Shen
et al., 1996). An unknown Pol I transcription factor is also
cleaved by 3CPro, resulting in inhibition of Pol I transcrip-
tion in virus-infected cells (Rubinstein and Dasgupta,
1987; Rubinstein et al., 1992).
While the TATA or initiator elements carry out low-level
transcription (basal transcription), high-level or activated
transcription from many cellular and viral promoters re-
quires interaction of multiple upstream transcription fac-
tors. These elements have been found to be required for
induction by exogenous substrates such as hormones,
phorbol esters, serum, and cyclic AMP (Montminy et al.,
1986). One such transcriptional activator is p53. It func-
tions as a typical sequence-specific transcription activa-
tor (Farmer et al., 1992; Kern et al., 1991) that binds as a
tetramer (Jeffrey et al., 1995) to four tandem, alternatively
inverted copies of a 5-bp consensus sequence (Cho et
al., 1994; Halazonetis and Kandil, 1993). Considerable
evidence suggests that the transcriptional stimulatory
activity is necessary for p53 to function as a tumor
suppressor (Vogelstein and Kinzler, 1992). It is thought
that p53 transcriptionally activates genes that prevent
entry into S phase and/or genes required for apoptosis.
p53 activation requires that it binds to TFIID (Liu et al.,
1993; Thut et al., 1995) through interactions with TATA-
box-binding protein (TBP)-associated factors (TAFs) and
potentially with TBP (Thut et al., 1995). Recent biochem-
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p53 occurs through direct or indirect interactions with
both TFIIB and TFIID (Liu and Berk, 1995).
Previous reports from our laboratory have shown that
at least two transcriptional activator proteins, the cyclic
AMP-responsive element-binding protein (CREB) and the
octamer-binding transcription factor (Oct-1), are cleaved
by the viral protease 3CPro both in vitro and in vivo,
leading to transcriptional inactivation of these activators
(Kliewer et al., 1990; Yalamanchili et al., 1997b,c). In this
paper we have examined the transcriptional activator
p53 in poliovirus-infected HeLa cells. We show that po-
liovirus infection of HeLa cells leads to degradation of
the transcription activator p53. Incubation of in vitro
translated p53 in reticulocyte lysate or p53 present in
crude HeLa cell-free extracts with 3CPro leads to degra-
dation of p53. However, purified p53 is not cleaved by
3Cpro in vitro until supplemented with uninfected HeLa
cell extracts. Thus, both 3CPro and one or more cellular
activities appear to be required for p53 degradation.
Initial characterization shows that the cellular activity
required for p53 degradation is heat labile and is inacti-
vated by vaccinia virus infection of HeLa cells. These
results suggest that, unlike other transcription factors
that are directly cleaved by the viral protease 3CPro, p53
degradation by 3CPro may be indirect.
RESULTS
p53 is degraded in poliovirus-infected HeLa cells
To investigate whether the transcriptional activator
p53 is cleaved during infection of HeLa cells with polio-
virus, cell-free extracts were prepared from mock- and
poliovirus-infected cells and examined by Western blot
analysis using a mouse monoclonal antibody against an
epitope corresponding to amino acids 11–25 of p53. The
antibody recognized the p53 polypeptide from mock-
infected cells (Fig. 1A, lane 1). In cells infected with
poliovirus for 4 h, p53 was almost totally absent (Fig. 1A,
lane 2). Although the intensity of the p53 band was
drastically reduced, we were unable to detect any
cleaved products of p53 in infected cell extracts. The
precise reason for this is not known. The proteolyzed
fragments may be unstable in HeLa cell extracts. Alter-
natively, the monoclonal antibody may somehow have
failed to detect the proteolyzed fragments containing the
epitope. As a positive control, a similar immunoblot was
developed with anti-Oct-1 antibodies. We have previ-
ously shown that Oct-1 is cleaved in poliovirus-infected
cells. As can be seen in Fig. 1B, the proteolytic cleaved
product of Oct-1 was clearly detected in the infected cell
extract (lanes 1 and 2). A number of host cell transcrip-
tion factors including TBP, Oct-1, TFIIIC, and CREB are
cleaved by the poliovirus-encoded protease 3CPro both in
vitro and in vivo (Clark et al., 1991, 1993; Yalamanchili et
al., 1996, 1997b,c). We, therefore, examined whether 3CProwas responsible for p53 degradation. A mutant poliovirus
(Se1 3C-02; Dewalt and Semler, 1987) which has a valine
to alanine substitution at amino acid 54 of 3CPro was
used to determine whether it was defective in p53 deg-
radation. Upon infection of HeLa cells, this virus pro-
duces very little active 3CPro and consequently has a
small plaque phenotype. It still grows to nearly wild-type
(wt) titers because poliovirus overproduces 3CPro and
other viral proteins (Dewalt and Semler, 1987). It is im-
portant to note that this mutant protease is not totally
defective but is much less active than the wild-type
protease. Earlier studies from our laboratory demon-
strated that this mutant virus was defective in shutting off
cellular RNA Pol II and III transcription (Clark et al., 1991;
Yalamanchili et al., 1996). HeLa cells were either mock-
infected or infected with wt poliovirus or the Se1 3C-02
mutant and cells were harvested at various times postin-
fection. Cell-free extracts were then prepared and sub-
jected to Western blot analysis following sodium dodecyl
sulfate–polyacrylamide gel electrophoresis (SDS–PAGE).
Two p53 antibodies which recognized a 53-kDa protein
from mock-, PV-, and Se1 3C-02-infected cells were used
in this experiment (Fig. 2). The p53 antibody used in Fig.
2A was a mouse monoclonal antibody which recognized
an epitope corresponding to amino acids 11–25. The p53
antibody used in Fig. 2B was a goat polyclonal antibody
raised against full-length p53. A mouse monoclonal an-
tibody to b-tubulin (Fig. 2A) or a mouse monoclonal
antibody to actin (Fig. 2B) was also used in the Western
blot analysis as a loading control. While the intensity of
the b-tubulin band remained relatively constant among
mock- and Se1 3C-02-infected extracts (Fig. 2A, lanes
1–5 and 11–15), a significant increase in the intensity of
the b-tubulin band was observed in PV-infected cell
FIG. 1. p53 is degraded in poliovirus-infected HeLa cells. (A) HeLa
cells were either mock-infected (lane 1) or poliovirus-infected (lane 2)
for 4 h at an m.o.i. of 25. Cell extracts were prepared and 200 mg of
each extract was analyzed by Western blotting using an antibody to the
p53 protein. (B) Two hundred micrograms each of extracts prepared
from mock-infected (lane 1) and poliovirus-infected (lane 2) cells at 4 h
postinfection was examined by Western blot analysis using anti-Oct-1
antibody. Full-length proteins and proteolyzed product(s) are shown by
arrows. The migration of molecular weight markers is as indicated.extracts particularly at 4 and 5 h postinfection (lanes
6–10). Actin seemed to be a better loading control as its
ded on
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The intensity of the p53 band did not change significantly
up to 2 h of infection. At 3 and 4 h postinfection, the
intensity of the p53 band was reduced to 70 and 18% of
the zero time control. At 5 h postinfection p53 was no longer
detectable (Fig. 2A, lane 10). In comparison, the levels of
p53 in mock- and Se1 3C-02-infected cells remained rela-
tively constant throughout infection. These results suggest
that the viral protease 3C was responsible for degrada-
tion of p53 in poliovirus-infected HeLa cells.
3CPro-mediated degradation of p53 in vitro
To determine whether 3CPro is indeed capable of de-
grading p53, bacterially expressed, purified His-tagged
3CPro was incubated with the uninfected HeLa cell ex-
tract and the resulting reactions were analyzed by West-
ern blotting using the p53 antibody. Incubation of mock-
infected extract with 0.8 mg of 3CPro resulted in significant
degradation (;75%) of p53 compared to the control (Fig.
3A, lanes 1 and 2). At a higher concentration of 3CPro, no
p53 was detectable (Fig. 3A, lane 3).
FIG. 2. Kinetics of p53 degradation in wt- and Se1 3C-02-infected He
of 25 PFU with poliovirus (lanes 6–10) or mutant poliovirus (Se1 3C-02) (l
taken at 0 (lanes 1, 6, 11), 2 (lanes 2, 7, 12), 3 (lanes 3, 8, 13), 4 (lanes 4
onto a 12% SDS–PAGE gel, transferred to nitrocellulose, and probed w
(B) HeLa spinner culture (;2 3 108) cells were infected at an m.o.i. o
11–15) or mock-infected (lanes 1–5). Following adsorption, samples we
14), and 5 h (lanes 5, 10, 15). HeLa whole-cell extract (200 mg) was loa
a polyclonal anti-p53 antibody and a monoclonal anti-actin antibody.To confirm the above results, p53 was translated in
vitro in the presence of [35S]methionine in rabbit reticu-locyte lysate, and the labeled protein was incubated with
various concentrations of purified 3CPro. As can be seen
in Fig. 3B, at a very low concentration of 3CPro (80 ng), p53
degradation was only 8% compared to the control (com-
pare lanes 1 and 2). However, p53 was almost totally
degraded (3 and 6%, respectively) at 0.8 and 8 mg of 3Cpro
(Fig. 3B, lanes 3 and 4). To rule out the possibility that a
contaminating Escherichia coli protease was degrading
p53, a mutant 3CPro having a single amino acid substitu-
tion at the active site (3C C147S) was expressed and
purified from E. coli (Hammerle et al., 1991). As expected,
8 mg of the mutant protease was totally inactive in de-
grading in vitro translated p53 (Fig. 3B, lane 5). Thus,
both genetic and biochemical results suggest that deg-
radation of p53 in poliovirus-infected HeLa cells is me-
diated by the viral protease 3CPro.
Initial characterization of p53 degradation in
poliovirus-infected cells
In order to determine whether proteolytic degradation
products of p53 can be detected early during the reac-
s. (A) HeLa spinner culture (;2 3 108) cells were infected at an m.o.i.
–15) or mock-infected (lanes 1–5). Following adsorption, samples were
and 5 h (lanes 5, 10, 15). HeLa whole-cell extract (200 mg) was loaded
onoclonal anti-p53 antibody and a monoclonal anti-b-tubulin antibody.
U with poliovirus (lanes 6–10) or mutant poliovirus (Se1 3C-02) (lanes
n at 0 (lanes 1, 6, 11), 2 (lanes 2, 7, 12), 3 (lanes 3, 8, 13), 4 (lanes 4, 9,
to a 12% SDS–PAGE gel, transferred to nitrocellulose, and probed withLa cell
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, 9, 14),
ith a m
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utant,
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quots of the reactions were withdrawn at 0 min, 30 min,
1 h, 1.5 h, and 2 h (Fig. 4A, lanes 1–5). Only 10% reduction
in the intensity of the labeled p53 band was observed at
30 min postincubation compared to the zero time control
(Fig. 4A, compare lanes 1 and 2). However, 1 h after the
FIG. 3. Poliovirus-encoded 3CPro degrades p53 in vitro. (A) Two hund
(lane 1) and in the presence of 0.8 mg (lane 2) and 8 mg (lane 3) of the
antibody. (B) In vitro translated, [35S]methionine-labeled p53 in reticuloc
(lane 2), 0.8 (lane 3), and 8 mg (lane 4) of 3CPro or 8 mg of the 3CPro m
described under Materials and Methods. Migration of marker proteins
FIG. 4. Characterization of p53 degradation. (A) Kinetics of 3CPro-in
reticulocyte lysates was incubated with 1 mg of 3CPro at 30°C for 0 min
proteins were analyzed by SDS–PAGE. The 14C-labeled molecular weigh
is indicated on the right. (B) 3CPro-catalyzed degradation of p53 at variou
was incubated without (lanes 1, 3, 5, 7, and 9) or with 0.5 mg 3CPro (lane
5 and 6), 37°C (lanes 7 and 8), and 65°C (lanes 9 and 10). Labeled proteins we
on the left.reaction close to half (;47%) of the total p53 was de-
graded (Fig. 4A, lane 3). Yet no cleaved products of p53
were detectable at this time point. Continued incubation
through 2 h resulted in further disappearance of p53
without concomitant generation of proteolyzed products
(Fig. 4A, lanes 4 and 5).
rograms of mock-infected HeLa extract was incubated in the absence
pe 3CPro. Reactions were analyzed by Western blotting using anti-p53
ate was incubated in the absence (lane 1) and in the presence of 0.08
3C C147S (lane 5). Labeled proteins were analyzed by SDS–PAGE as
wn on the left.
degradation of p53. [35S]Methionine-labeled p53 translated in rabbit
), 30 min (lane 2), 1 h (lane 3), 1.5 h (lane 4), and 2 h (lane 5). Labeled
ers are shown on the left (in kilodaltons). The position of full-length p53
eratures. [35S]Methionine-labeled p53 translated in reticulocyte lysates
6, 8, and 10) at 4°C (lanes 1 and 2), 24°C (lanes 3 and 4), 30°C (lanesred mic
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s temp
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p53 with 3CPro showed very little degradation at 4°C (Fig.
4B, lanes 1 and 2), and approximately 50% degradation
was observed at 24°C (lanes 3 and 4). Increasing the
incubation temperature to 30 and 37°C resulted in close
to 70% and more than 94% degradation, respectively (Fig.
4B, lanes 5–8). Increasing the temperature to 65°C al-
most completely blocked cleavage (Fig. 4B, lanes 9 and
10). Again, no proteolytic fragments of p53 were detect-
able during the reaction at various temperatures.
The ubiquitin pathway of protein degradation is ATP-
dependent and operates in rabbit reticulocytes, HeLa
cells, and many other eukaryotic cells (Finley and Chau,
1991; Ciechanover et al., 1991). Previous studies have
shown that many oncogenic viral proteins (such as the
papilloma virus E6 transforming protein) induce degra-
dation of p53 via the ubiquitin pathway (Scheffner et al.,
1990).
p53 is one of the many proteins in the cell which is
marked for protein degradation. Such proteins are poly-
ubiquitinated and then rapidly degraded by proteo-
somes. In order to determine whether ubiquitination
played a role in the p53 degradation, we examined the
effect of a proteosome inhibitor on HeLa cells during
poliovirus infection. HeLa cell spinner cultures were in-
cubated with (Fig. 5A, lanes 4–6) and without (lanes 1–3)
the proteosome inhibitor MG132 (10 mM). The cells were
incubated in the presence of the inhibitor for 15 h at
37°C. The cells were then mock-infected or poliovirus-
infected. A significant decrease in the level of p53 can be
seen between mock- and pv-infected cells both in the
absence and in the presence of MG132 (Fig. 5A, com-
pare lanes 1 and 3, and lanes 4 and 6). As a control,
tumor necrosis factor a (TNF-a) (20 ng/ml) was used as
a stimulator of Ikb-a ubiquitination. A 32% decrease in
the amount of Ikb-a was seen when unstimulated HeLa
cells (Fig. 5A, lane 1) were compared with the level of
Ikb-a in HeLa cells stimulated with TNF-a (Fig. 5A, lane
2). However, in HeLa cells pretreated with the proteo-
some inhibitor MG132, ubiquitination of Ikb-a was inhib-
ited even in the presence of TNF-a (Fig. 5A, lane 5). Thus,
a proteosome inhibitor was ineffective in blocking polio-
virus-mediated degradation of p53 under conditions
which actively inhibited degradation of Ikb-a.
Because the ubiquitin pathway requires ATP hydroly-
sis, degradation of proteins by this pathway is inhibited
by the nonhydrolyzable ATP analogue, g-thio ATP (Finley
and Chau, 1991). In order to further determine whether
the poliovirus 3CPro-mediated degradation of p53 in-
volves the ubiquitin pathway, the effect of g-thio ATP on
p53 degradation was investigated. In vitro translated,
labeled p53 (in reticulocyte lysate) was incubated with
3CPro in the absence and in the presence of g-thio ATP.
As can be seen in Fig. 5B, inclusion of g-thio ATP in the
Proreaction did not significantly inhibit 3C -catalyzed deg-
radation of p53 (compare lanes 3 and 4 with lane 2). Infact, almost 90% of p53 was degraded in the presence of
10 mM g-thio ATP compared to the control (Fig. 5B, lanes
1 and 3). Thus, the ubiquitin pathway does not appear to
be involved in 3CPro-mediated degradation of p53.
Degradation of p53 by 3CPro in HeLa cells is inhibited
by vaccinia virus infection
To examine whether 3CPro directly cleaves p53 it was
necessary to purify p53 from HeLa cells. Because p53 is
not an abundant protein in HeLa cells, a recombinant
vaccinia virus harboring an epitope-tagged p53 was
used to infect HeLa cells and extracts were prepared
from these cells. Western analysis using the p53 anti-
body showed that a significant amount of p53 was made
in these cells (Fig. 6A, lane 1). No endogenous p53 was
detectable when 10 or 20 mg of uninfected HeLa cell
FIG. 5. The ubiquitination pathway does not appear to be involved in
3CPro-mediated degradation of p53. (A) MG132 does not inhibit 3CPro-
induced degradation of p53. HeLa cells were incubated with (lanes
4–6) and without (lanes 1–3) the proteosome inhibitor MG132 (10 mM)
for 15 h at 37°C. The cells were then mock-infected (lanes 1 and 4) or
poliovirus-infected (lanes 3 and 6) for 5 h or incubated with TNF-a (20
ng/ml) for 6 h at 37°C. HeLa whole-cell extracts (150 mg) were loaded
onto a 5–14% SDS–PAGE gel, transferred to nitrocellulose, and probed
with a p53 polyclonal antibody, an Ikb-a polyclonal antibody, and an
actin monoclonal antibody. (B) g-thio ATP does not inhibit 3CPro-induced
degradation of p53. In vitro translated [35S]methionine-labeled p53 in
reticulocyte lysate was incubated in the absence (lane 1) and in the
presence of 1 mg 3CPro (lanes 2–4) and with 5 mM g-thio ATP (lane 4)
and 10 mM g-thio ATP (lane 3) or without g-thio ATP (lane 2). Lanes 5
and 6 show cleavage of [35S]methionine-labeled TBP in the absence
(lane 5) and in the presence of 1 mg 3CPro (lane 6). Molecular weight
markers are shown on the left.extracts was used in this assay (data not shown). Inter-
estingly, when purified 3CPro was incubated with the
ence o
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p53 was not observed (Fig. 6A, compare lane 2 with
lanes 3–5). In fact, even very high concentrations of
purified 3CPro (8 mg) were unable to mediate degradation
of p53 (Fig. 6A, compare lane 2 with lane 5). Under
similar conditions, however, much smaller amounts of
3CPro were sufficient to cleave transcription factor TBP in
the same extract (Fig. 6B), indicating that the 3CPro activ-
ity was not blocked in extracts prepared from vaccinia-
infected cells. It is important to note that degradation of
endogenous HeLa p53 by 3CPro was detected in our
previous experiment with as little as 0.8 mg of 3CPro (see
Fig. 3A). To investigate the effect of vaccinia infection on
endogenous p53 levels, HeLa cells were infected with vac-
cinia virus for 20 h. Extracts were prepared from these cells
and analyzed by Western blot with p53 antibody (Fig. 6C).
Increasing amounts of purified 3CPro were incubated with
the cellular extracts. As little as 0.5 mg of 3CPro in mock-
infected extracts decreased the levels of endogenous p53
by 54% (Fig. 6C, lanes 1 and 2). When 1 or 2 mg of 3CPro was
added (Fig. 6C, lanes 3 and 4), the level of p53 present
decreased by 89 and 95.5%, respectively, whereas in vac-
cinia virus-infected extracts, the level of p53 did not de-
crease even when 2 mg of 3Cpro was added (lane 8). It
appears, therefore, that vaccinia virus infection some-
how interferes with 3CPro-mediated cleavage of p53.
Vaccinia virus is known to use a novel strategy to
prevent IL-1 action (anti-inflammatory response) through
the inactivation of IL-1b converting enzyme (ICE). Two
vaccinia virus-encoded proteins, SPI-2 and CrmA, inhibit
FIG. 6. Vaccinia virus inhibits 3CPro-mediated degradation of p53. (A) H
Methods. Cell-free extracts were prepared and analyzed by Wester
VV-ep53-infected cell extract was incubated in the absence of purified
presence of 0.08 (lane 3), 0.8 (lane 4), and 8 (lane 5) mg of purified 3CPro.
antibody following incubation in the absence (lane 1) and in the prese
mock-infected or vaccinia virus-infected with recombinant vaccinia viru
analyzed by Western blotting using the anti-p53 monoclonal antibody.
incubated in the absence (lanes 1 and 5, respectively) and in the pres
2 (lanes 4 and 8, respectively) mg of purified 3CPro.ICE (Caspase 1), preventing the intracellular conversion
of the inactive precursor IL-1b to the active secreted form(Ray et al., 1992). In this way CrmA functions as a viral
anti-inflammatory molecule. To investigate whether the
ICE inhibition by vaccinia-encoded proteins results in the
inhibition of the cellular activity necessary for 3Cpro-me-
diated degradation of p53, we utilized the ICE inhibitor,
Z-VAD-fmk (Barco et al., 2000). HeLa cells were preincu-
bated for 16 h with caspase inhibitor (Z-VAD-fmk) or
caspase inhibitor control (F-A-fmk). Cells were then
mock- or PV-infected [multiplicity of infection (m.o.i.) of
25] for 5 h. Whole-cell extracts were then subjected to
Western blot analysis using anti-p53 and anti-b-tubulin
antibodies. Extracts from cells which were mock-infected
in the absence (Fig. 7, lane 1) or in the presence of either
20 mM caspase I inhibitor (lane 3) or 20 mM caspase
inhibitor control (lane 4) all showed relatively similar
levels of p53. In all extracts infected with PV (Fig. 7, lanes
2 and 5–10), p53 was completely degraded regardless of
whether caspase I inhibitor was present (lanes 5–7) or
not (lanes 2 and 8–10). Western blot analysis of the same
extracts with anti-PARP antibody was performed to dem-
onstrate that the caspase inhibitor and caspase inhibitor
control were working under the same assay conditions
(data not shown). An additional control was used in
which Western blot analysis of the extracts was per-
formed with anti-CREB antibody to demonstrate that the
caspase inhibitor and caspase inhibitor control had no
significant effect on 3Cpro catalytic activity (data not
shown). These results indicate that the IL-1b converting
enzyme is not the cellular activity inhibited in vaccinia
lls were infected with vaccinia virus as described under Materials and
ing using the anti-p53 monoclonal antibody. Ten or 20 mg of total
anes 1 and 2, respectively) and 20 mg of extract was incubated in the
same extracts were also used in Western blot analysis using anti-TBP
0.08 (lane 2) and 0.8 (lane 3) mg of purified 3CPro. (C) HeLa cells were
expresses T7 at an m.o.i. of 10. Cell-free extracts were prepared and
undred micrograms of total mock- or VV-T7-infected cell extracts was
f 0.5 (lanes 2 and 6, respectively), 1 (lanes 3 and 7, respectively), andeLa ce
n blott
3CPro (l
(B) The
nce of
s which
Two hvirus-infected extracts that is necessary for 3C-mediated
degradation of p53.
ns wer
rch Pr
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p53 degradation
To address the possibility that one or more HeLa cell
proteins (or activities) might be involved in 3CPro-medi-
ated p53 degradation, epitope-tagged p53 was purified
from the recombinant vaccinia virus-infected cells by
affinity chromatography and its degradation by 3CPro was
examined in the presence and in the absence of unin-
fected HeLa cell extract by Western blot analysis. Addi-
tion of 0.8 mg of purified 3CPro to the affinity-purified
epitope-tagged p53 decreased the intensity of the p53
band by 25% of the control (compare lanes 1 and 2 in Fig.
8). At the lowest concentration of HeLa extract (0.5 mg),
degradation of p53 by 3CPro was not significant (Fig. 8,
lane 3). However, at 1 and 2 mg of HeLa cell extract,
75–85% of 3CPro-mediated degradation of p53 was ob-
served compared to the control (Fig. 8, lanes 4 and 5). At
these concentrations of HeLa cell extracts (1 and 2 mg),
the endogenous p53 was beyond detection by Western
analysis (data not shown). Two micrograms of HeLa
FIG. 7. Caspase inhibitor study. Cell-free extracts from mock- and p
monoclonal antibody. Mock (lanes 1, 3, and 4) and poliovirus infections
and in the presence of 5 mM (lane 5), 10 mM (lane 6), and 20 mM (lanes
20 mM (lanes 4 and 10) caspase inhibitor control (F-A-fmk). The infectio
bacterially expressed p53 Western blotting standard (Oncogene Resea
FIG. 8. 3CPro-induced cleavage of p53 requires a cellular activity. Aff
3CPro (lane 2), 0.8 mg 3CPro and 0.2 mg HeLa cell extract (lane 3), 0.8 mg
(lane 5), 0.8 mg 3CPro plus 2 mg wheat germ extract (lane 6), 0.8 mg 3C
mg reticulocyte lysate (lane 8), 2 mg HeLa extract alone (lane 9), 2 mg wheat
After 2 h of incubation, p53 was analyzed by Western blotting using an anti-pextract in the absence of 3CPro had no significant effect
(Fig. 8, lane 9). Heating the HeLa extract at 85°C for 10
min almost totally abolished its p53 degradation activity
in the presence of 3CPro (Fig. 8, lane 7). 3CPro-mediated
p53 degradation in the presence of 2 mg of rabbit reticu-
locyte lysates was more complete than that observed
with 2 mg of HeLa extract (Fig. 8, compare lane 8 with
lane 5). Incubation of purified p53 with reticulocyte lysate
alone had no significant effect on p53 degradation (Fig.
8, lane 11). Approximately 40% degradation of p53 was
observed in the presence of 2 mg wheat germ extract (in
the presence of 3CPro) compared to the control (lane 6).
These results suggest that both reticulocyte lysate and
HeLa cell extracts contain activities that are required for
3CPro-mediated degradation of purified p53 and that this
activity in HeLa cell extract is heat labile.
Fractionation of cellular activity
In order to isolate the cellular activity involved in the
3CPro-mediated degradation of p53, 9 liters of HeLa cells
us-infected HeLa cells were analyzed by Western blot using anti-p53
2, 5, 6, 7, 8, 9, and 10) were performed in the absence (lanes 1 and 2)
7) caspase inhibitor (Z-VAD-fmk) or 5 mM (lane 8), 10 mM (lane 9), and
e allowed to proceed for 5 h at 37°C. Lane 11 contains a recombinant,
oducts).
rified p53 was incubated at 30°C for 2 h alone (lane 1) or with 0.8 mg
us 1 mg HeLa extract (lane 4), 0.8 mg of 3CPro plus 2 mg of HeLa extract
2 mg heated (85°C, 10 min) HeLa extract (lane 7), 0.8 mg 3CPro plus 2oliovir
(lanes
3 andinity-pu
3CPro pl
Pro plusgerm extract alone (lane 10), or 2 mg of reticulocyte lysates (lane 11).
53 antibody.
267POLIOVIRUS 3CPro-MEDIATED DEGRADATION OF p53was used to make nuclear extracts. The nuclear extracts
were then precipitated with finely ground ammonium
sulfate to 40, 80, and 100% saturation. These fractions
were tested for 3CPro-mediated p53 degradation activity.
The majority of the p53 degradative activity was ob-
served in the 40–80% fraction (data not shown). The
40–80% ammonium sulfate fraction was further fraction-
ated over a phosphocellulose column. The column was
eluted with Buffer D containing 0.3, 0.6, and 1 M KCl.
These fractions were tested for 3C-mediated p53 degra-
dation activity (Fig. 9A, lanes 3–7). The majority of the
activity was detected in the 0.6 M KCl elution fraction
(Fig. 9A, lane 6). The phosphocellulose 0.6 M KCl fraction
did not show as much activity as the nuclear extract (Fig.
9A, lanes 6 and 2) because of dilution during the chro-
matographic steps. The activity in this fraction was fur-
ther tested for the heat lability observed previously. Ali-
quots of the dialyzed and concentrated 0.6 M KCl fraction
were preincubated for 5 (Fig. 9B, lanes 2 and 4) or 10
(Fig. 9B, lanes 3 and 5) min at 45°C (lanes 2 and 3) or
65°C (lanes 4 and 5) and then used to measure their
ability to degrade p53 in the presence of 3CPro. Signifi-
cant activity was observed in the aliquot preincubated for
FIG. 9. Fractionation of cellular activity. (A) HeLa cell nuclear extracts
were precipitated with ammonium sulfate at 40, 80, and 100% satura-
tion. The 40–80% ammonium sulfate sample was then loaded onto a
phosphocellulose column and eluted in Buffer D containing 0.3, 0.6,
and 1 M KCl. Affinity-purified p53 (100 ng) was incubated for 4 h at 30°C
alone (lane 1), with 0.2 mg 3CPro and 100 mg of mock nuclear extract
(MNE) (lane 2), with 0.2 mg 3CPro and 10 mg of the flow from the
phosphocellulose column (lane 3), with 0.2 mg 3CPro and 10 mg of the
phosphocellular column wash (lane 4), with 0.2 mg 3CPro and 10 mg of
0.3 M PC (phosphocellulose elution) fraction (lane 5), with 0.2 mg 3CPro
and 10 mg of 0.6 M PC (lane 6), and with 0.2 mg 3CPro and 4.5 mg of 1
M PC (lane 7). (B) Preincubation of 16.5 mg of HeLa cell nuclear extract
fractionate 0.6 M PC was carried out for 5 min at 45°C (lane 1), 10 min
at 45°C (lane 2), 5 min at 65°C (lane 3), and 10 min at 65°C (lane 4).
Affinity-purified p53 (60 ng) and 0.2 mg of 3C were added to each
sample and incubated for 4 h at 30°C. Results were analyzed by
Western blot with an anti-p53 monoclonal antibody.5 min at 45°C (Fig. 9B, lane 2) compared to the buffer-
treated control (lane 1). Preincubation of the 0.6 M KClfraction at 45°C for 10 min, however, resulted in almost
60% loss of activity compared to the control (Fig. 9B, lane
3). Heating the 0.6 M fraction at 65°C for 5 and 10 min
resulted in total loss of the p53 degradation activity (Fig.
9B, lanes 4 and 5). These results indicate that the cellular
activity can be fractionated from HeLa cell extracts and
is temperature sensitive.
DISCUSSION
Poliovirus-encoded protease 3CPro, responsible for the
proteolytic processing of viral precursor polypeptides,
also cleaves and inactivates a number of cellular tran-
scription factors. RNA polymerase II transcription factors
required for both basal (TBP) and activated transcription
(CREB, Oct-1) are inactivated by 3CPro in virus-infected
cells. Here we report that the transcriptional activator
and tumor suppressor p53 is degraded in poliovirus-
infected cells by a mechanism which appears to involve
not only 3CPro but also a cellular activity. Thus, unlike
other transcription factors that are cleaved directly by
3CPro, degradation of p53 by 3CPro appears to be indirect.
The evidence that 3CPro is required for p53 degradation
comes from both genetic and biochemical studies. First,
a mutant poliovirus (Se1 3C-02) defective in the 3C-
protease function is ineffective in catalyzing p53 degra-
dation in infected cells compared to the wild-type virus
(Fig. 2). Second, a purified preparation of bacterially
expressed 3CPro is capable of catalyzing degradation of
endogenous p53 in HeLa cell extract or p53 synthesized
in reticulocyte lysate by in vitro translation (Fig. 3). Only
the wild-type protease and not an inactive mutant pro-
tease was able to degrade p53 (Fig. 3). One of the
differences between the cleavage of other transcription
factors (such as TBP, CREB, Oct-1) and p53 by 3CPro was
that no distinct proteolytically cleaved products of p53
were detectable both in vitro and in vivo. The precise
reason for this is not known. It is possible that the p53
antibodies used were unable to react with the cleaved
products. Alternatively, cleaved products may have been
degraded quickly by cellular proteases. The 3CPro-cata-
lyzed degradation of p53 may not involve the ubiquitin
pathway of protein degradation because p53 degrada-
tion in poliovirus-infected cells is not inhibited by the
proteosome inhibitor, MG132 (Fig. 5A).
Many DNA tumor viruses appear to inhibit p53 func-
tion, which apparently leads to cellular transformation. It
is believed that the p53 transcriptional activator function
is necessary for p53 to function as a tumor suppressor
(Vogelstein and Kinzler, 1992). The large T antigen of
SV-40 forms a complex with p53, inhibiting its DNA-
binding activity and consequently its transcriptional ac-
tivity (Bargonetti et al., 1992; Farmer et al., 1992). Inter-
estingly, the human papilloma virus type 16 (HPV-16) E6
protein complexes with p53 and, in cooperation with a
268 WEIDMAN ET AL.cellular protein, promotes polyubiquitination of p53, re-
sulting in its degradation (Scheffner et al., 1990).
The evidence that p53 is not directly cleaved by 3CPro
came from the experimental result that infection of cells
with a recombinant vaccinia virus expressing the p53
protein resulted in the lack of p53 degradation in these
extracts by 3CPro (Fig. 7). Indeed, purified p53 is not
degraded by 3CPro and is degraded only when incubated
with both 3CPro and HeLa cell extract (Fig. 8). Finally, we
were able to partially purify the cellular activity required
for 3CPro-mediated degradation of p53. The activity re-
quired along with 3CPro to degrade p53 appears to be
heat labile, suggesting that it is a protein (Fig. 9). Reticu-
locyte lysates appear to contain a considerable amount
of this activity.
The fact that vaccinia virus inhibits the cellular activity
required for p53 degradation suggests that it may belong
to one of those inflammatory response proteins (en-
zymes) that are inhibited by vaccinia virus (Ray et al.,
1992). It is now well established that a vaccinia virus
gene product (p38) [cytokine response modifier (Crm A)
protein] inhibits IL-1b maturase (ICE protease), a pro-
tease involved in the processing of the IL-1b precursor to
mature IL-1b. It is possible that the poliovirus 3CPro ac-
tivates a similar cellular protease, which in turn de-
grades p53. In fact, the poliovirus 3CPro has been shown
to induce apoptosis in HeLa cells (Barco et al., 2000).
The 3CPro-induced apoptosis is blocked by the caspase
inhibitor Z-VAD-fmk, suggesting that caspase 1 (ICE pro-
tease) may be responsible for 3CPro-induced apoptosis.
The experiments reported here, however, suggest that
the cellular activity required for p53 degradation is prob-
ably not the ICE protease as degradation is not inhibited
by the ICE inhibitor Z-VAD-fmk (Fig. 7). The concept of
indirect cleavage of cellular proteins by a viral protease
already exists for the poliovirus 2A protease. It is be-
lieved that 2APro activates a cellular enzyme which then
cleaves the cap-binding protein necessary for cap-de-
pendent translation leading to cellular translation shut-
off (Etchison et al., 1982; Lloyd et al., 1986; Krausslich and
Wimmer, 1988; Lawson and Semler, 1990). However,
some recent reports suggest that the 2APro is capable of
cleaving the cap-binding protein directly (Haghighat et
al., 1996; Sommergruber et al., 1994). In addition, cleav-
age of the poliovirus capsid precursor (P1) by the viral
protease 3CD is facilitated by a cellular cofactor. This
cofactor facilitates recognition of the P1 precursor (Blair
et al., 1993). It was previously found that the cellular
protein human heat shock protein 70 (HSP70) is associ-
ated with the capsid precursor P1 of poliovirus and
coxsackievirus B1 in infected HeLa cells. It was ob-
served that anti-virion serum coimmunoprecipitated
HSP70 from virus-infected cell extracts, but not from
mock-infected cell extracts (Macejak and Sarnow, 1992).
ProThe mechanism by which both the 3C and the cel-
lular activity participate in p53 degradation is not known.A likely scenario is that 3CPro may activate a cellular
protease which in turn degrades p53. Alternatively, inter-
action of one or more cellular proteins with p53 may lead
to alteration of p53 secondary structure, resulting in
3CPro-mediated cleavage. Preliminary experiments, how-
ever, have shown that preincubation of the cellular ac-
tivity (0.6 M wash from phosphocellose column) with
3CPro, but not with purified p53, significantly increases
the kinetics of p53 degradation in vitro (data not shown).
Thus, an interaction between the cellular factor(s) and
3CPro may result in modification and/or activation of the
cellular activity required for p53 degradation.
A number of viruses including poliovirus affect the
balance between apoptosis-inducing and apoptosis-
suppressing functions that ultimately help viral replica-
tion and spread of virus infection (Teodoro and Branton,
1997; Tolskaya et al., 1995; Agol et al., 1998). While
regulated expression of 3CPro has been shown to induce
apoptosis (Barco et al., 2000), degradation of p53 in
poliovirus-infected HeLa cells (this report) could be a
mechanism by which apoptosis could be delayed or
prevented. Thus, 3CPro-induced degradation of p53 in
PV-infected cells could not only be involved in inhibition
of transcriptional activation but also result in delay or
prevention of apoptosis. The latter could help ensure that
progeny viruses are made and released without interfer-
ence from apoptosis.
Future studies will focus on the purification and iden-
tification of the cellular activity required for 3Cpro-medi-
ated degradation of p53 from HeLa cells and/or rabbit
reticulocytes. Such studies should shed more light onto
the mechanisms by which poliovirus manipulates cellu-
lar functions for its own benefit.
MATERIALS AND METHODS
Cells and viruses
HeLa cells were grown in spinner culture in minimum
essential medium (Gibco BRL) supplemented with 5%
calf serum, 1 g glucose per liter, and 104 units per liter
penicillin or as monolayers in Dulbecco’s modified Ea-
gle’s medium (Gibco BRL) supplemented with 5% new-
born calf serum, 5% fetal bovine serum, and 104 units per
liter of penicillin/streptomycin. Cells were infected with
poliovirus type 1 (Mahoney strain) at a multiplicity of
infection of 25, as previously described (Dasgupta, 1983).
HeLa cells were also infected with a poliovirus mutant
Se1 3C-02 at a multiplicity of infection of 25, as previ-
ously described (Clark et al., 1991). Vaccinia virus infec-
tion of HeLa cells was performed as described previ-
ously (Yew et al., 1994).
Preparation of extracts
Nuclear extracts were prepared from mock- and po-
liovirus-infected HeLa cells as previously described (Dig-
nam et al., 1983).
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pTM.1-ep53, expressing epitope-tagged p53, was con-
structed by PCR amplification of human p53 from the
pcDNA-p53 plasmid (Liu et al., 1993), using primers that
introduce an NcoI site and the amino acid sequence
MYPYDVPDYA (influenza virus epitope) at the 59 end and
a BamHI site at the 39 end. The amplified DNA fragments
were cloned between the NcoI and the BamHI sites of
the pTM.1 vector (Elroy-Stein et al., 1989). Recombinant
vaccinia virus expressing epitope-tagged human p53
was constructed by the procedure previously described
by Elroy-Stein et al. (1989). Correct recombinant vaccinia
virus was confirmed by Western analysis of cell extracts
prepared from infected cells. Recombinant vaccinia virus
(VV-ep53) was plaque purified and viral titers were de-
termined by plaque assay on HeLa cells.
Epitope-tagged p53 was purified from vaccinia virus-
infected HeLa cell monolayers. Approximately 5.5 3 108
cells were infected with VV-ep53 and V-TF7-3, which
expresses the T7 RNA polymerase, at an m.o.i. of 10 and
5, respectively. Infection was stopped at 30 h postinfec-
tion and whole-cell extracts were made by freeze/thaw-
ing the cells in phosphate-buffered saline (PBS). One
milliliter of nuclear extract was incubated with 20 ml of
packed beads of protein A–Sepharose covalently linked
to monoclonal antibody HA.11 (BabCo) at 4°C for 16 h
(Liu et al., 1993). The HA.11 affinity beads were washed
three times with 0.4 M KCl buffer D [20 mM HEPES (pH
7.9), 20% glycerol, 0.2 mM EDTA, 0.5 mM dithiothreitol, 0.5
mM PMSF] and two times with the same buffer contain-
ing 0.1 M KCl. Epitope-tagged p53 was eluted with 100 ml
of the influenza virus HA peptide (Sigma/BabCo) (YPYD-
VPDYA) at 100 mg/ml in the same buffer containing 0.1 M
KCl. The purified epitope-tagged p53 was dialyzed
against buffer D containing 0.1 M KCl overnight at 4°C in
a dialysis membrane with a molecular weight cutoff of
30,000.
Protease reactions
The poliovirus protease 3CPro was PCR amplified from
poliovirus infectious cDNA pT7PV1 and cloned into
pQE30 (Qiagen) in the BamHI and HindIII sites as de-
scribed previously (Yalamanchili et al., 1996). 3CPro DNA
was used for transforming E. coli expression cells
M15pRep4, and the plasmid 3CM15pRep4 at an optical
density of 0.7 was induced with 1 mM isopropyl thiogal-
actoside for 4 h. The histidine-tagged 3CPro was purified
from induced cells by nondenaturing nickel affinity chro-
matography as previously described (Hammerle et al.,
1991; Nicklin et al., 1988). The indicated amounts of 3CPro
were incubated with mock-infected extracts, affinity-pu-
rified p53 or in vitro translated p53 at 30°C for 4 h as
previously described (Yalamanchili et al., 1996). Reac-
tions were performed in the presence of 100–200 mg ofHeLa cell extract or rabbit reticulocyte lysate (Promega)
unless otherwise indicated.
Antibodies
The p53 antibodies consisted of either a mouse mono-
clonal antibody (DO-1, Santa Cruz) raised against an
epitope corresponding to amino acids 11–25 or a goat
polyclonal antibody raised against full-length p53 (FL-
393, Santa Cruz Biotechnologies). The Oct-1 antibody
(C-21, Santa Cruz Biotechnologies) was a rabbit poly-
clonal antibody which recognizes the carboxy terminus
of Oct-1 of human origin. The b-tubulin antibody (KMX-1,
Boehringer Mannheim) was a mouse monoclonal anti-
body from mouse–mouse hybrid cells. The actin antibody
(JLA20, Oncogene Research Products) was a mouse
monoclonal antibody raised against chicken cytoskeletal
proteins and recognized a-, b-, and g-actin. The PARP
antibody (Boehringer Mannheim) was a rabbit polyclonal
antibody. The TBP antibody (SI-1, Santa Cruz Biotechnol-
ogies) was a rabbit polyclonal antibody prepared by
immunization with full-length E. coli-produced TBP of
human origin. The Ikb-a antibody (C-21, Santa Cruz Bio-
technologies) was a goat polyclonal antibody raised
against the carboxy terminus of Ikb-a.
Western blot analysis
Proteins were separated by SDS–14% PAGE. The sep-
arated proteins were electrophoretically blotted onto ni-
trocellulose. The nitrocellulose was blocked for 1 h with
1% blocking reagent (Boehringer Mannheim). The blot
was probed with the specific primary antibody for 1 h. All
corresponding secondary antibodies were horseradish
peroxidase conjugates obtained from Boehringer Mann-
heim. The immunoblot was developed using the chemi-
luminescence detection system (Pierce) as described by
the manufacturer.
Proteosome inhibitor studies
HeLa cell spinner cultures (7.2 3 107 cells) were pre-
incubated with the proteosome inhibitor MG132 (Sigma)
at a concentration of 10 mM for 15 h at 37°C. The cells
were then mock-infected, poliovirus-infected, or treated
with TNF-a (20 ng/ml, Sigma) for 5–6 h at 37°C. The cells
were pelleted and washed twice with ice-cold PBS, and
whole-cell extracts were made and assayed by Western
blot analysis.
Caspase inhibitor studies
HeLa cell monolayers (2.5 3 109 cells) were preincu-
bated with the caspase inhibitor Z-VAD-fmk or with the
caspase inhibitor control F-A-fmk (Enzyme Systems
Products), in the indicated amounts. The preincubation
lasted approximately 16 h at 37°C. The cells were then
mock- or poliovirus-infected and incubated for 5 h at
270 WEIDMAN ET AL.37°C. The cells were scraped in PBS, and whole-cell
extracts were made and assayed by Western blot anal-
ysis.
Partial purification of the cellular activity from HeLa
cells
Nuclear extract was prepared from 9 liters of HeLa cell
spinner culture as previously described (Digman et al.,
1983). Nuclear extracts were precipitated with finely
ground ammonium sulfate at 40, 80, and 100% saturation.
The pellets were resuspended in Buffer D and dialyzed
against this buffer overnight at 4°C. The dialyzed ammo-
nium sulfate fractions were assayed for p53 degradative
activity as described for the protease reaction above.
The reminder of the 40–80% ammonium sulfate saturated
fraction was run over a phosphocellulose column follow-
ing the protocol provided by the manufacturer (Sigma).
The column was equilibrated with Buffer D containing 0.1
M KCl and eluted with Buffer D containing 0.3, 0.6, and 1
M KCl. These fractions were dialyzed against Buffer D
overnight at 4°C. Aliquots of each elution were stored at
270°C for future use.
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